The new Medicare 'Access' code for AI in chronic care is priced too low to be profitable if humans are kept in the loop. This clever incentive design forces providers to adopt genuine AI-driven leverage rather than simply relabeling human effort, a first for healthcare technology.

The company's next product will provide objective brain state data, much like a CGM provides constant glucose readings. This allows for data-driven mental health treatment, moving beyond subjective checklists and enabling closed-loop therapies with neuromodulators, fundamentally changing diagnostics and care.

Innovative medical devices get a temporary 'tracking' CPT code. To secure permanent reimbursement, companies must demonstrate widespread physician adoption, but achieving that adoption is nearly impossible without the insurance coverage they are trying to obtain.

While the FDA is often blamed for high trial costs, a major culprit is the consolidated Clinical Research Organization (CRO) market. These entrenched players lack incentives to adopt modern, cost-saving technologies, creating a structural bottleneck that prevents regulatory modernization from translating into cheaper and faster trials.

While positioned as a clinical decision support tool rather than a formal diagnostic, the technology is still reimbursable under existing CPT codes. This provides a direct financial incentive for providers, a critical advantage in a healthcare system where new, unreimbursed technologies face steep adoption hurdles.

Our ability to generate and test therapeutic hypotheses in silico is rapidly outpacing the slow, expensive conventional clinical trial system. Without regulatory reform, the pipeline of promising drugs will remain stuck, preventing breakthroughs from reaching patients. The science is solvable; the system is not.

AdaptDx plans to first target specific, high-need clinical conditions like heart failure to secure FDA approval and reimbursement. This clinical validation and revenue stream will then fund the miniaturization and expansion into the broader consumer health and wellness market, bridging the gap between medical care and daily life.

The US is losing the biotech race not just at the FDA, but due to slow hospital Institutional Review Boards (IRBs) and contracting. A Phase 1 trial takes four weeks in China, while a simple university survey in the US can take over a year for approval, creating a major competitive disadvantage.

The company first targets patients with disabilities, a clear medical need. By restoring functions like speech, they create platforms for enhanced abilities (e.g., prompting AI with thoughts), paving the way for a wider consumer market where the risk-benefit calculation shifts over time.